Tiaopi huxin recipe improved endothelial dysfunction and attenuated atherosclerosis by decreasing the expression of caveolin‐1 in ApoE‐deficient mice
The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclero...
Saved in:
Published in | Journal of cellular physiology Vol. 234; no. 9; pp. 15369 - 15379 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.09.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE−/−) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE
−/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE
−/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE
−/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE
−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS.
Our findings show that tiaopi huxin recipe (TPHXR) improved the endothelial function and reduced atheromatous lesions in ApoE−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in atherosclerosis mice vasculature. TPHXR may represent a promising intervention in patients with artherosclerosis. |
---|---|
AbstractList | The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE
) mice were fed a high-fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low-dose, medium-dose, and high-dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein-2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor-α (TNF-α), hs-CRP, IL-6, and IL-1β, in mice plasma were analyzed by enzyme-linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high- and medium-dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE
mice. The high- and medium-dose TPHXR treatment, but not the low-dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium-dependent vasorelaxation in ApoE
mice. High- and medium-dose TPHXR, but not low-dose TPHXR, decreased the expression of cav-1, NF-κB p50, NF-κB p65, ICAM1, VCAM-1, TNF-α, IL-6, and IL-1β in the vasculature of ApoE
mice. Enzyme-linked immunosorbent assay analysis indicated that high- and medium-dose TPHXR decreased the levels of TNF-α, IL-6, hs-CRP, and IL-1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE
mice. This result may be due to the decreased expression of caveolin-1 and NF-κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS. Abstract The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE −/− ) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE −/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE −/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE −/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE −/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS. The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE−/−) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE −/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE −/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE −/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE −/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS. Our findings show that tiaopi huxin recipe (TPHXR) improved the endothelial function and reduced atheromatous lesions in ApoE−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in atherosclerosis mice vasculature. TPHXR may represent a promising intervention in patients with artherosclerosis. The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of TPHXR treatment of atherosclerosis (AS) has not been fully elucidated. In this study, we have aimed to explore the potential antiatherosclerotic effect of TPHXR and its underlying mechanisms. Male ApoE knockout (ApoE−/−) mice were fed a high‐fat diet for 12 weeks and were randomly divided into four groups: the control group, and the low‐dose, medium‐dose, and high‐dose TPHXR groups. The nitric oxide (NO) levels in arterial tissue and human umbilical vein endothelial cells (HUVECs) were measured by diaminofluorescein‐2 diacetate staining. Vasorelaxation of mice aorta was performed by wire myograph. Inflammatory cytokines, including tumor necrosis factor‐α (TNF‐α), hs‐CRP, IL‐6, and IL‐1β, in mice plasma were analyzed by enzyme‐linked immunosorbent assay. Western blot analysis was applied to observe protein expression. Oil Red O staining was utilized for the quantification of atherosclerotic plaques. Results showed that 4 weeks of high‐ and medium‐dose TPHXR treatment by oral gavage reduced atheromatous lesions in ApoE−/− mice. The high‐ and medium‐dose TPHXR treatment, but not the low‐dose treatment, promoted eNOS phosphorylation, increased NO levels and improved endothelium‐dependent vasorelaxation in ApoE−/− mice. High‐ and medium‐dose TPHXR, but not low‐dose TPHXR, decreased the expression of cav‐1, NF‐κB p50, NF‐κB p65, ICAM1, VCAM‐1, TNF‐α, IL‐6, and IL‐1β in the vasculature of ApoE−/− mice. Enzyme‐linked immunosorbent assay analysis indicated that high‐ and medium‐dose TPHXR decreased the levels of TNF‐α, IL‐6, hs‐CRP, and IL‐1β. In conclusion, our findings show that TPHXR improved the endothelial function and reduced atheromatous lesions in ApoE−/− mice. This result may be due to the decreased expression of caveolin‐1 and NF‐κB and, hence, the attenuated inflammatory response in AS mice vasculature. TPHXR may represent a promising intervention in patients with AS. |
Author | Lin, Tong Li, Junzhe Zhou, Chi Wang, Dan Wu, Wei Luo, Chuanjin Liu, Sen Wen, Junmao Wan, Jindong Yang, Yi Wang, Peijian |
Author_xml | – sequence: 1 givenname: Junmao surname: Wen fullname: Wen, Junmao organization: Guangzhou University of Chinese Medicine – sequence: 2 givenname: Tong surname: Lin fullname: Lin, Tong organization: Guangzhou University of Chinese Medicine – sequence: 3 givenname: Wei surname: Wu fullname: Wu, Wei organization: First Affiliated Hospital of Guangzhou University of Chinese Medicine – sequence: 4 givenname: Yi surname: Yang fullname: Yang, Yi organization: The First Affiliated Hospital, Chengdu Medical College – sequence: 5 givenname: Chuanjin surname: Luo fullname: Luo, Chuanjin organization: First Affiliated Hospital of Guangzhou University of Chinese Medicine – sequence: 6 givenname: Chi surname: Zhou fullname: Zhou, Chi organization: First Affiliated Hospital of Guangzhou University of Chinese Medicine – sequence: 7 givenname: Jindong surname: Wan fullname: Wan, Jindong organization: The First Affiliated Hospital, Chengdu Medical College – sequence: 8 givenname: Sen surname: Liu fullname: Liu, Sen organization: The First Affiliated Hospital, Chengdu Medical College – sequence: 9 givenname: Dan surname: Wang fullname: Wang, Dan organization: The First Affiliated Hospital, Chengdu Medical College – sequence: 10 givenname: Peijian surname: Wang fullname: Wang, Peijian email: wpjmed@aliyun.com organization: The First Affiliated Hospital, Chengdu Medical College – sequence: 11 givenname: Junzhe orcidid: 0000-0002-3988-542X surname: Li fullname: Li, Junzhe email: 2015404734@qq.com organization: Guangdong Hospital of Chinese Medicine |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30729525$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kc1u1DAQxy1URLcLB14AWeICh7T-iLfxsVqVL1WCQzlHznjMepXYwU5K98YjcOX1-iT1dgsHJKTRzEjz898e_0_IUYgBCXnJ2SlnTJxtYTwVDW_qJ2TBmT6v6pUSR2RRZrzSqubH5CTnLWNMaymfkWPJzoVWQi3I72tv4ujpZr71gSYEPyL1w5jiDVqKwcZpg703PbW77OYAk4-BmmCpmSYMs5lw324wxQz9PvtMux21CAlN9uEbLUOKt2PCnPdno6NgbjD2Ptz9_MVpufZijJelt-g8eAwTHTzgc_LUmT7ji8e6JF_fXV6vP1RXn99_XF9cVSCVrCt0yMFZLRoFdiWdqVdN11m34kZY4TQoYZB1TnPUTtdKMwVNLUF16Ay4Ti7Jm4Nu2fn7jHlqB58B-94EjHNuhRCaaa6ZKOjrf9BtnFMor3ugGsVliSV5e6Cg_EZO6Nox-cGkXctZu_erLX61D34V9tWj4twNaP-SfwwqwNkB-OF73P1fqf20_nKQvAdHlqce |
CitedBy_id | crossref_primary_10_1016_j_heliyon_2023_e18653 crossref_primary_10_1080_21691401_2019_1646264 crossref_primary_10_1155_2022_1852330 crossref_primary_10_14336_AD_2019_09603 crossref_primary_10_3389_fphar_2020_546825 crossref_primary_10_1155_2020_8683404 crossref_primary_10_3748_wjg_v26_i10_1029 |
Cites_doi | 10.1016/j.atherosclerosis.2015.04.783 10.3892/ijmm.2014.1646 10.3390/ijms18061260 10.1016/j.cmet.2009.06.003 10.1159/000486155 10.1016/j.cardiores.2007.04.012 10.2174/138161212802481237 10.1161/CIRCULATIONAHA.109.192666 10.1159/000131083 10.1146/annurev.physiol.64.081501.155952 10.1172/JCI11871 10.1159/000374074 10.13193/j.issn.1673‐7717.2014.10.052 10.1016/j.amjcard.2007.02.001 10.3969/j.issn.1004‐745X.2015.12.067 10.1097/00041433-200410000-00005 10.1097/MCA.0000000000000082 10.7501/j.issn.1674‐6376.2013.04.016 10.1161/01.ATV.21.2.201 10.1038/82176 10.1074/jbc.271.44.27237 10.1161/01.ATV.0000101182.89118.E5 10.1016/j.jacc.2016.11.005 10.1111/j.1365‐2796.2006.01621.x 10.1007/s11655‐012‐1123‐x 10.1159/000370010 10.1038/35025203 10.1161/STR.0b013e3181fcb238 10.4268/cjcmm20120723 10.1161/HYPERTENSIONAHA.115.06223 10.1016/j.ijcard.2007.08.077 10.1007/s00441‐013‐1767‐7 10.1016/S0140‐6736(17)32247‐X |
ContentType | Journal Article |
Copyright | 2019 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2019 Wiley Periodicals, Inc. |
DBID | NPM AAYXX CITATION 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
DOI | 10.1002/jcp.28184 |
DatabaseName | PubMed CrossRef Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | PubMed CrossRef Genetics Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
DatabaseTitleList | PubMed CrossRef Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Biology |
EISSN | 1097-4652 |
EndPage | 15379 |
ExternalDocumentID | 10_1002_jcp_28184 30729525 JCP28184 |
Genre | article Journal Article |
GrantInformation_xml | – fundername: National Natural Science Foundation of China funderid: 81403225; 81400289 – fundername: The training project of Top‐notch Creative Talents of Guangzhou University of Chinese Medicine funderid: BKBJCX2018003 – fundername: Program of Sichuan Youth Science and Technology Foundation in China funderid: 2016JQ0032 – fundername: the Innovation Team Project Department of Education of Sichuan Province funderid: 18TD0030 – fundername: National Natural Science Foundation of China grantid: 81400289 – fundername: the Innovation Team Project Department of Education of Sichuan Province grantid: 18TD0030 – fundername: The training project of Top-notch Creative Talents of Guangzhou University of Chinese Medicine grantid: BKBJCX2018003 – fundername: Program of Sichuan Youth Science and Technology Foundation in China grantid: 2016JQ0032 – fundername: National Natural Science Foundation of China grantid: 81403225 |
GroupedDBID | --- -DZ -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 9M8 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEFU ABEML ABIJN ABJNI ABPPZ ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AETEA AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIAGR AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AUFTA AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BQCPF BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMB EMOBN F00 F01 F04 F5P FEDTE G-S G.N G8K GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ H~9 IH2 IX1 J0M JPC KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M56 MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MVM MXFUL MXSTM N04 N05 N9A NEJ NF~ NNB O66 O9- OHT OIG P2P P2W P2X P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RWI RWR RX1 RYL S10 SAMSI SUPJJ SV3 TN5 TWZ UB1 UPT V2E V8K VQP W8V W99 WBKPD WH7 WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WXSBR WYB WYISQ X7M XG1 XJT XOL XPP XSW XV2 Y6R YQT YZZ ZGI ZXP ZZTAW ~IA ~WT NPM AAYXX CITATION 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c3534-efe1cfd9285cd63fa468bbdf61a2d2f9c52ae0bf91e9f945905c843c5befacfb3 |
IEDL.DBID | DR2 |
ISSN | 0021-9541 |
IngestDate | Fri Aug 16 09:46:24 EDT 2024 Sat Oct 26 04:14:34 EDT 2024 Thu Sep 26 20:25:19 EDT 2024 Sat Sep 28 08:17:00 EDT 2024 Sat Aug 24 01:17:55 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Keywords | atherosclerosis caveolin-1 tiaopi huxin recipe inflammation endothelial dysfunction |
Language | English |
License | 2019 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3534-efe1cfd9285cd63fa468bbdf61a2d2f9c52ae0bf91e9f945905c843c5befacfb3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-3988-542X |
PMID | 30729525 |
PQID | 2229851351 |
PQPubID | 1006363 |
PageCount | 11 |
ParticipantIDs | proquest_miscellaneous_2229091902 proquest_journals_2229851351 crossref_primary_10_1002_jcp_28184 pubmed_primary_30729525 wiley_primary_10_1002_jcp_28184_JCP28184 |
PublicationCentury | 2000 |
PublicationDate | September 2019 2019-Sep 2019-09-00 20190901 |
PublicationDateYYYYMMDD | 2019-09-01 |
PublicationDate_xml | – month: 09 year: 2019 text: September 2019 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | Journal of cellular physiology |
PublicationTitleAlternate | J Cell Physiol |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | e_1_2_8_1_12_1 e_1_2_8_1_11_1 e_1_2_8_1_36_1 e_1_2_8_1_14_1 e_1_2_8_1_33_1 e_1_2_8_1_13_1 e_1_2_8_1_34_1 Wang H. (e_1_2_8_1_31_1) 2008; 14 e_1_2_8_1_32_1 e_1_2_8_1_10_1 e_1_2_8_1_30_1 e_1_2_8_1_8_1 e_1_2_8_1_9_1 Zhang J. T. (e_1_2_8_1_35_1) 2015; 30 e_1_2_8_1_27_1 e_1_2_8_1_26_1 e_1_2_8_1_29_1 e_1_2_8_1_28_1 e_1_2_8_1_23_1 e_1_2_8_1_22_1 e_1_2_8_1_25_1 e_1_2_8_1_21_1 e_1_2_8_1_20_1 e_1_2_8_1_2_1 e_1_2_8_1_3_1 e_1_2_8_1_6_1 e_1_2_8_1_7_1 e_1_2_8_1_4_1 e_1_2_8_1_5_1 e_1_2_8_1_19_1 e_1_2_8_1_16_1 e_1_2_8_1_39_1 e_1_2_8_1_15_1 Ma Y. (e_1_2_8_1_24_1) 2012; 18 e_1_2_8_1_18_1 e_1_2_8_1_37_1 e_1_2_8_1_17_1 e_1_2_8_1_38_1 |
References_xml | – ident: e_1_2_8_1_17_1 doi: 10.1016/j.atherosclerosis.2015.04.783 – ident: e_1_2_8_1_33_1 doi: 10.3892/ijmm.2014.1646 – ident: e_1_2_8_1_34_1 doi: 10.3390/ijms18061260 – ident: e_1_2_8_1_38_1 – ident: e_1_2_8_1_6_1 doi: 10.1016/j.cmet.2009.06.003 – ident: e_1_2_8_1_25_1 doi: 10.1159/000486155 – ident: e_1_2_8_1_19_1 doi: 10.1016/j.cardiores.2007.04.012 – ident: e_1_2_8_1_29_1 doi: 10.2174/138161212802481237 – ident: e_1_2_8_1_21_1 doi: 10.1161/CIRCULATIONAHA.109.192666 – ident: e_1_2_8_1_5_1 doi: 10.1159/000131083 – ident: e_1_2_8_1_28_1 doi: 10.1146/annurev.physiol.64.081501.155952 – ident: e_1_2_8_1_4_1 doi: 10.1172/JCI11871 – ident: e_1_2_8_1_30_1 doi: 10.1159/000374074 – ident: e_1_2_8_1_18_1 doi: 10.13193/j.issn.1673‐7717.2014.10.052 – volume: 18 start-page: 140 year: 2012 ident: e_1_2_8_1_24_1 article-title: Effects of serum containing tanyu tongzhi fang on expression of NF‐κB and ICAM‐1 in HUVECs injured by ox‐LDL publication-title: Chinese Journal of Experimental Traditional Medical Formulae contributor: fullname: Ma Y. – ident: e_1_2_8_1_7_1 doi: 10.1016/j.amjcard.2007.02.001 – ident: e_1_2_8_1_37_1 doi: 10.3969/j.issn.1004‐745X.2015.12.067 – ident: e_1_2_8_1_8_1 doi: 10.1097/00041433-200410000-00005 – ident: e_1_2_8_1_14_1 doi: 10.1097/MCA.0000000000000082 – ident: e_1_2_8_1_36_1 doi: 10.7501/j.issn.1674‐6376.2013.04.016 – ident: e_1_2_8_1_16_1 doi: 10.1161/01.ATV.21.2.201 – ident: e_1_2_8_1_3_1 doi: 10.1038/82176 – ident: e_1_2_8_1_10_1 doi: 10.1074/jbc.271.44.27237 – volume: 14 start-page: 598 year: 2008 ident: e_1_2_8_1_31_1 article-title: Vascular endothelial and atherosclerosis publication-title: Medical Recapitulate contributor: fullname: Wang H. – ident: e_1_2_8_1_9_1 doi: 10.1161/01.ATV.0000101182.89118.E5 – ident: e_1_2_8_1_2_1 doi: 10.1016/j.jacc.2016.11.005 – ident: e_1_2_8_1_13_1 doi: 10.1111/j.1365‐2796.2006.01621.x – ident: e_1_2_8_1_15_1 doi: 10.1007/s11655‐012‐1123‐x – ident: e_1_2_8_1_20_1 doi: 10.1159/000370010 – ident: e_1_2_8_1_22_1 doi: 10.1038/35025203 – ident: e_1_2_8_1_39_1 – ident: e_1_2_8_1_12_1 doi: 10.1161/STR.0b013e3181fcb238 – ident: e_1_2_8_1_23_1 doi: 10.4268/cjcmm20120723 – ident: e_1_2_8_1_32_1 doi: 10.1161/HYPERTENSIONAHA.115.06223 – ident: e_1_2_8_1_11_1 doi: 10.1016/j.ijcard.2007.08.077 – ident: e_1_2_8_1_26_1 doi: 10.1007/s00441‐013‐1767‐7 – ident: e_1_2_8_1_27_1 doi: 10.1016/S0140‐6736(17)32247‐X – volume: 30 start-page: 4006 year: 2015 ident: e_1_2_8_1_35_1 article-title: Overview about preparation methods of serum containing Chinese medicine publication-title: China Journal of Traditional Chinese Medicine and Pharmacy contributor: fullname: Zhang J. T. |
SSID | ssj0009933 |
Score | 2.3821528 |
Snippet | The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the mechanism of... Abstract The Tiaopi Huxin recipe (TPHXR) is widely used in traditional Chinese medicine for the clinical treatment of coronary heart disease. However, the... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 15369 |
SubjectTerms | Aorta Apolipoprotein E Arteriosclerosis Atherosclerosis Cardiovascular disease Cardiovascular diseases Caveolin caveolin‐1 Coronary artery disease Cytokines Endothelial cells endothelial dysfunction Endothelium Enzymes Heart diseases Herbal medicine High fat diet Inflammation Inflammatory response Intercellular adhesion molecule 1 Lesions Nitric oxide Oils & fats Phosphorylation Plaques Staining tiaopi huxin recipe Traditional Chinese medicine Tumor necrosis factor Tumor necrosis factor-TNF Umbilical vein Vasodilation |
Title | Tiaopi huxin recipe improved endothelial dysfunction and attenuated atherosclerosis by decreasing the expression of caveolin‐1 in ApoE‐deficient mice |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fjcp.28184 https://www.ncbi.nlm.nih.gov/pubmed/30729525 https://www.proquest.com/docview/2229851351 https://search.proquest.com/docview/2229091902 |
Volume | 234 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9UwFD-MgeCLH5sf1SlRRHzpXds0vQ0-XebGGCgiG-xBKPlkVZcWeyu7Pvkn-Oq_51_iSdreMUUQX0ogaU-bnJP8cnryOwDP5hpRQCFErCRqcF4mNubKprFkiUKAwKkOh8RevykOT_KjU3a6AS-nszADP8Ta4eYtI8zX3sCF7HYvSUM_qHbmqYw8F2hK5z6c69W7S-ooPqaRDyEILE8nVqEk213feXUt-gNgXsWrYcE5uAnvp1cd4kw-zvqlnKmvv7E4_ue33IIbIxAli0FzbsOGcVuwvXC4CT9fkeckhIYGn_sWXBsyVq624cdxLZq2Jmf9Re2IZ8ZoDamDY8JoYpz2B7o-oU4Tver8munHnQiniefxdD0iW19ERWk6FIvXuiNyRXRAr95vQbCSmIsxPteRxhIlvhifW-jnt-8pQbGLttnHsjae_QIXTXKOs90dODnYP947jMfsDrGijOaxsSZVVvOsZEoX1Iq8KKXUtkhFpjPLFcuESaTlqeGW54wnTJU5VUwaK5SV9C5susaZ-0BK3EhSfJhMBQKknAo5F1SrOc43ObeZjeDpNM5VO5B4VANdc1Zh11eh6yPYmTSgGu24q3y2c8SklKURPFlXowX63yrCmaYf2iDq4kkWwb1Bc9ZSqCdmZxmL4EUY_7-Lr4723obCg39v-hCuI34bQ952YHP5uTePECMt5eNgDL8AgLoSZA |
link.rule.ids | 315,783,787,1378,27936,27937,46306,46730 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB6VIgQXfloKgQIGIcQl2ySOs7HEZVVaLaWtENpKvaDIvyK0TSJ2F3U58QhceT2ehLGTbFUQEuISWbKTSewZ-_Nk_A3A86FGFJAJESqJGpzmkQ25snEoWaQQIHCq_SGxg8NsfJTuHbPjFXjVn4Vp-SGWDjdnGX6-dgbuHNJbF6yhn1QzcFxG6RW4iuZOXeKG1-8vyKN4l0jeByGwNO55haJka3nr5dXoD4h5GbH6JWf3FnzoX7aNNDkZzGdyoL7-xuP4v19zG252WJSMWuW5AyumWoP1UYX78LMFeUF8dKh3u6_BtTZp5WIdfkxKUTcl-Tg_LyviyDEaQ0rvmzCamEq7M12nqNZEL6Zu2XRDT0SliaPyrOYIbl0RdaWeoli8llMiF0R7AOtcFwQriTnvQnQrUluixBfj0gv9_PY9Jih21NQ7WNbGEWDguknOcMK7C0e7O5PtcdgleAgVZTQNjTWxsponOVM6o1akWS6ltlksEp1YrlgiTCQtjw23PGU8YipPqWLSWKGspBuwWtWVuQ8kx70kxYfJWCBGSqmQQ0G1GuKUk3Kb2ACe9QNdNC2PR9EyNicFdn3huz6AzV4Fis6Up4VLeI6wlLI4gKfLajRC92dFVKaet20QePEoCeBeqzpLKdRxs7OEBfDSK8DfxRd72-984cG_N30C18eTg_1i_83h24dwA-FcFwG3Cauzz3PzCCHTTD72lvELdbwWfA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIhAXHi2PhQIGIcQl2yS2s7E4rUpXpUBVoVbqASnyU6SlScTuoi4nfgJX_h6_hLGTbFUQEuISWbKTSewZ-_Nk_A3As5FBFJBJGWmFGszy2EVCuyRSPNYIEAQ14ZDYu71s55DtHvGjFXjZn4Vp-SGWDjdvGWG-9gbeGLd5Thp6rJuhpzJil-AyyxD5ekT0_pw7SnR55EMMAmdJTysUp5vLWy8uRn8gzIuANaw4kxvwoX_XNtDkZDifqaH--huN439-zE243iFRMm5V5xas2GoN1scV7sJPF-Q5CbGhwem-BlfalJWLdfhxUMq6KcnH-VlZEU-N0VhSBs-ENcRWxp_o-oRKTcxi6hdNP_BEVoZ4Is9qjtDWF1FT6imKxWs5JWpBTICv3nFBsJLYsy5AtyK1I1p-sT650M9v3xOCYsdNvY1lYz39Ba6a5BSnu9twONk-2NqJuvQOkaacssg6m2hnRJpzbTLqJMtypYzLEpma1AnNU2lj5URihROMi5jrnFHNlXVSO0XvwGpVV_YekBx3khQfphKJCIlRqUaSGj3CCYcJl7oBPO3HuWhaFo-i5WtOC-z6InT9ADZ6DSg6Q54WPt05glLKkwE8WVajCfr_KrKy9bxtg7BLxOkA7raas5RCPTM7T_kAXoTx_7v4YndrPxTu_3vTx3B1_9WkePt6780DuIZYrgt_24DV2ee5fYh4aaYeBbv4BTTPFSs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tiaopi+huxin+recipe+improved+endothelial+dysfunction+and+attenuated+atherosclerosis+by+decreasing+the+expression+of+caveolin-1+in+ApoE-deficient+mice&rft.jtitle=Journal+of+cellular+physiology&rft.au=Wen%2C+Junmao&rft.au=Lin%2C+Tong&rft.au=Wu%2C+Wei&rft.au=Yang%2C+Yi&rft.date=2019-09-01&rft.eissn=1097-4652&rft.volume=234&rft.issue=9&rft.spage=15369&rft.epage=15379&rft_id=info:doi/10.1002%2Fjcp.28184&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9541&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9541&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9541&client=summon |